PIK3CA and hyperlipidemia: Nie et al. [42] found that Rutecarpine ameliorates hyperlipidemia and hyperglycemia in fat-fed, streptozotocin-treated rats via regulating the IRS-1/PI3K/AKT signaling pathway.